The Winship Cancer Institute (Winship) at Emory University is a university-based cancer center that supports, facilitates and coordinates all cancer research, cancer care and cancer-related education within Emory University, Winship is the first and only NCI-designated cancer center in the state of Georgia, the 8th most populous state in the union. As such, Winship is a transformative leader in integrating cancer research and care aimed at reducing the burden of cancer for the citizens of Georgia and the Southeastern region. Winship has a strong commitment to the inclusion of minorities in clinical research, with approximately 30% of participants in its clinical research trials in 2012 identified as African- American. Winship investigators are conducting innovative therapeutic and non-therapeutic trials across the oncology spectrum. The accomplishments presented in this application are highly relevant to Winship's participation in NCI National Clinical Trials Network (NCTN) and to the growing collaborative research opportunities available between the NCI NCTN network groups and Winship. Winship has participated in clinical trials conducted by all ten of the currently existing NCI-supported cancer cooperative groups. Over the past 5 years Winship investigators have accrued over 500 adult patients to cooperative group clinical trials at Emory University and its affiliates. We have seen a steady increase in accruals over this time period demonstrated by a greater than 50% increase in accruals between 2007 and 2012. This demonstrates the commitment of Winship to continue to provide benefit to our patients through innovative clinical research. Winship investigators have also led the accrual of over 488 young adult and adolescent patients to COG trials since 2007. During the same time period, Winship investigators have designed and/or chaired over 20 trials through the adult cooperative groups. The goal of this application is to sustain and increase the level of engagement between Winship and the NCTN and its network groups in terms of scientific and administrative leadership as well as accrual to NCTN trials.

Public Health Relevance

Winship investigators have played a major role in the national cooperative groups by providing leadership to various disease committees and groups. They have also been consistent contributors to patient accrual as evidenced by a steady Increase in number of patients accrued to cooperative group studies at Winship. Combined with our scientific strengths, patient resources, especially accrual of minority patients, Winship is wel positioned to make robust contributions to the NCTN.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Pillai, Rathi N; Behera, Madhusmita; Berry, Lynne D et al. (2017) HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer 123:4099-4105
Leng, Shuguang; Wu, Guodong; Klinge, Donna M et al. (2017) Gene methylation biomarkers in sputum as a classifier for lung cancer risk. Oncotarget 8:63978-63985
Butterfield, Lisa H; Zhao, Fengmin; Lee, Sandra et al. (2017) Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res 23:5034-5043
Belani, Chandra P; Dahlberg, Suzanne E; Rudin, Charles M et al. (2016) Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer 122:2371-8
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Langer, Corey J; Socinski, Mark A; Patel, Jyoti D et al. (2016) Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. Am J Clin Oncol 39:441-7
Owonikoko, Taofeek K; Dahlberg, Suzanne E; Khan, Saad A et al. (2015) A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). Lung Cancer 89:66-70
Hanna, Nasser H; Dahlberg, Suzanne E; Kolesar, Jill M et al. (2015) Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Cancer 121:2253-61
Herbst, Roy S; Gandara, David R; Hirsch, Fred R et al. (2015) Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res 21:1514-24

Showing the most recent 10 out of 58 publications